The Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) is the first and most challenging hurdle in reviewing the insurance reimbursement of new anticancer drugs.

A required step toward obtaining reimbursement listing, the committee has been nicknamed a "steep slope," giving many anticancer drugs a hard time.

The industry faced significant challenges this year as well.

New anticancer drugs from major global pharmaceuticals have been submitted for CDRC review but failed. Yet, some products passed the CDRC and successfully obtained reimbursement or expansion.

Medical Time reported this year's review outcomes and